The acyl-CoA dehydrogenases are a family of homologous mitochondrial flavoproteins involved in the catabolism of fatty acids and amino acids. Isobutyryl-CoA dehydrogenase is involved in the catabolism of valine and catalyzes the conversion of isobutyryl-CoA to methacrylyl-CoA. The crystal structure of isobutyryl-CoA dehydrogenase with and without substrate has been determined to 1.76Å resolution. The 
The exception is VLCAD, which is a membrane-bound homodimer with a subunit molecular mass of approximately 67kDa and is associated with the matrix face of the inner mitochondrial membrane (9) . Although the submitochondrial location and native 4 ACD is then reoxidized by ETF in a series of two, one-electron transfers (13) . As the enzyme names suggest, each of the fatty-acid β-oxidation enzymes have a characteristic pattern of substrate chain-length specificity that can overlap with those enzymes that are active towards longer or shorter substrates. There is also limited overlap in the specificity for branched chain substrates among IVD, IBD and SBCAD. A homologous group of enzymes are the peroxisomal acyl-CoA oxidases (ACOs) which also catalyze the α,β-dehydrogenation of acyl-CoA substrates to trans-2-enoyl-CoA. Unlike the ACDs, however, ACOs utilize molecular oxygen as the electron acceptor to form hydrogen peroxide in the process of re-oxidation. ACOs are homodimers with a subunit size of 75 kDa and contain one non-covalently bound FAD per subunit.
The structures of MCAD (14) , IVD (15) , and SCAD (16) as well as a bacterial SCAD (17) have been previously determined by x-ray crystallography. All of these enzymes share a similar fold with the major differences residing in the binding cavity.
With the high degree of similarity seen in the structures determined so far, the question of interest is what structural differences are responsible for the observed pattern of substrate specificity in this enzyme family. The structures determined thus far have shown that the presence of either longer or shorter amino acid side chains occludes the substrate binding cavity to varying degrees, controlling the length of substrate that can be accommodated in the binding pocket. This is further enhanced in the case of MCAD, which has a proline at the middle of the G helix that slightly alters the helix trajectory and deepens the bottom of the binding cavity (14) . In the case of IVD, a tyrosine that defines the side of the binding pocket in other ACDs is replaced with a glycine, resulting in the expansion of the binding pocket on the dimethylbenzene side of the FAD (15) . IBD has a leucine instead by guest on August 17, 2017 http://www.jbc.org/ Downloaded from of the tyrosine at this position in the binding pocket, so the structural basis for the binding pocket expansion must be different in IBD from that in IVD.
As a whole, deficiencies in the ACDs represent a significant group of metabolic disorders. In mammals, isovaleryl-CoA is converted to 3-methylcrotonyl-CoA by IVD, 2-methylbutyryl-CoA is converted to tiglyl-CoA by SBCAD, and isobutyryl-CoA is converted to methacrylyl-CoA by IBD. Of the branched chain specific ACDs, IVD deficiency was described earliest (18, 19) and therefore represents the largest patient population in the literature. SBCAD and IBD deficiencies were characterized recently, so only two patients have been reported with SBCAD deficiency (20, 21) and only one patient has been reported with IBD deficiency thus far (6, 22) . The IBD deficient patient was initially characterized by in vitro analysis of mitochondrial leucine, isoleucine and valine metabolic pathways (22) . Subsequently, DNA analysis showed that this patient was homozygous for an Arg280Gln mutation, and subsequent expression and characterization of this recombinant mutant confirmed the earlier in vitro diagnosis (6) .
In this manuscript we report the structure of human isobutyryl-CoA dehydrogenase in the uncomplexed form and in complex with product to 1.76Å resolution. The structure confirms the catalytic base, and comparison of the structure of IBD to those of IVD and SCAD identifies the structural differences between IBD and the other ACDs that are responsible for its substrate specificity. We have modeled the single reported mutation (6) as well as several other recently identified unreported mutations from patients with IBD deficiency to explain the structural basis of IBD deficiency.
Experimental Procedures

Purification and Crystallization of Human IBD.
The expression and purification of human IBD has been described elsewhere (6) .
Briefly Side chains were added to the poly-alanine model, and one round of rigid body refinement followed by positional refinement resulted in an R cryst of 50.1% and R free of 55.0%. The R free set comprises 10% of the total reflections and was cut out in shells. An initial round of manual fitting followed by simulated annealing and positional refinement lowered the R cryst and R free to 30.5% and 35.2% respectively. Model refinement was performed using CNS (25) 
Results and Discussion
Overall Topology and Structure of Isobutyryl-CoA Dehydrogenase
The basic fold of the IBD structure is very similar to that of the other ACDs (15) (16) (17) 31) . IBD is a homotetramer and the tetrameric arrangement of the monomers appears to be a dimer of dimers ( Therefore, the bound ligand had been modeled in as the reaction product, methacrylylCoA. However, the enzyme flavin in the complex is predominantly in the oxidized form as indicated by the yellow color of the crystal. The reduced flavin by the substrate must have been slowly reoxidized by molecular oxygen during the crystallization process. The presence of ligand in only two subunits suggests that lattice packing is such that in the two subunits the bound product is trapped, since the substrate was co-crystallized.
However, no symmetry-related molecules directly impinge on the substrate binding region in any of the subunits. There is also no evidence for allosterism in the reaction mechanism of any known ACD. Therefore, it is more likely that the concentration of the substrate/product became low enough for half-site saturation due to hydrolysis of the thioester linkage during the crystallization process.
There are minor differences in the structure between IBD and the other ACDs as illustrated in the peptide backbone overlay of IBD and MCAD in Figure 2B . The rmsd between IBD and the other ACDs varies from 1.1Å versus SCAD and IVD, 1.3Å versus MCAD, to 1.4Å versus bSCAD for α-carbons. There are several deletions and one insertion in the IBD structure when compared to the other ACDs ( Figure 3 ). The most significant difference is a deletion in the middle of helix E, and this is in a homologous position to the deletion seen in MCAD. This deletion occurs N-terminal to Met-106 and will be discussed below. All other differences are in loop regions and do not appear to be either structurally or functionally significant.
Catalytic Residue, Glu-376
This structure of IBD confirms the identity of the catalytic base as Glu-376. Glu-376 is located in a position homologous to the catalytic residue of MCAD, SCAD and bacterial SCAD whereas the catalytic residue in IVD lies in helix G ( Figure 3 and Table   2 ). The average distance (between monomers C and D) from the catalytic glutamate to the C2 atom of the substrate in IBD is 3.7Å and the distance from substrate C3 to the FAD N5 atom is 3.6Å, showing that the C2-C3 bond of the substrate almost exactly bisects the distance between the carboxylate of Glu-376 and the flavin ring. As in other ACD structures, this arrangement of the isoalloxazine ring of FAD, the C2 and C3 atoms of the thioester substrate, and the carboxylate of Glu-376 ( Figure 4A ) is ideally suited for abstraction of the pro-R hydrogen as a proton and transfer of the C3 pro-R hydrogen to the N5 atom of FAD as a hydride ion (10) . The carbonyl oxygen of the fatty-acyl moiety of the substrate makes hydrogen bonds to the 2'-hydroxyl of the FAD ribityl chain (2.8Å) and to the peptide backbone of Glu-376 (2.9Å). The corresponding distances in MCAD are also 2.8Å and 2.9Å, respectively (14) . These interactions are not only responsible for
proper orientation of the substrate, they are also crucial for polarization of the substrate and the lowering of the pKa of the C2 proton for abstraction by the catalytic base, Glu-376 (32) . A water molecule is conserved in the binding cavity of all IBD subunits, and is also present in the SCAD binding cavity. This water molecule lies within 2.8Å of the catalytic glutamate ( Figure 4A and 4B) in the substrate-bound monomers of IBD and in SCAD (which is a binary complex with acetoacetyl-CoA), whereas the corresponding distance is greater than 3.3Å in the unbound monomers in the IBD structure. This water molecule is most likely acting as the acceptor of the proton that is abstracted from the substrate by the catalytic glutamate.
Comparison Between Ligand-Bound and Unbound Subunits in IBD
MCAD is the only ACD whose structure has been reported with and without substrate (14) . These two MCAD structures have shown that there is no dramatic conformational change that accompanies the binding of substrate (rmsd 0.29Å for all α- 
Binding Pocket Comparisons and Structural Basis of Substrate Specificity
IBD is active towards isobutyryl-, S-2-methylbutyryl-, and propionyl-CoA (k cat /K m 0.8, 0.23 0.04 µM -1 s -1 ; K m 2.6, 18, 24 µM respectively), but is virtually inactive towards n-butyryl-, n-valeryl-and isovaleryl-CoA (6), suggesting that the 2-methyl group is crucial for activity. Table 2 of Ser-97 and Leu-98 (SCAD residues) and in common with MCAD Leu-103 ( Figure 3 ).
In IBD, the E-helix is further out of the binding cavity than in MCAD, so the general effect is that IBD Met-106 is further out of the binding cavity than MCAD Leu-103, thus making the cavity wider at this point ( Figure 4B ). The base of the cavity in IBD is defined by Ile-103, while Ala-99 helps to define the base of the binding pocket in IVD.
However, Ile-103 in IBD is positioned further into the binding cavity relative to IVD and SCAD ( Figures 5B and 5C ), which in turn makes the cavity shallower and wider at its base to accommodate the 2-methyl group of the substrate in IBD. The presence of Leu-375 in IBD instead of a tyrosine also contirubutes, in part, to the widening of the cavity at its base. Thus, while the binding cavity of IVD is expanded to one side to accommodate the 3-methyl group of isovaleryl-CoA, the general contour of the IBD binding cavity is more restricted near the top and more expanded at the base to accept the 2-methyl group of the substrate. The cavity of SCAD, which is specific for short, straight chain acylCoA substrates, is both narrow and shallow ( Figure 5 ). A and C were overlaid and the molecular surface generated using a 1.4Å probe. Color scheme is the same as panel A. The binding cavity surface of monomer C is shaded in red and monomer A is in green. All amino acid residues that display large conformational changes upon ligand binding (except Leu-251 for clarity) were included in this panel.
Color scheme is the same as above. This figure was generated with Grasp (39), Molscript/POVScript+ (36, 37) , and Raster3D (38). Figure 1A . 
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